Mirion (MIR) Q1 2026 earnings review
Top-Line Surges on M&A and Nuclear Momentum, But Cash Flow and Margins Lag
Mirion delivered a massive top-line quarter, with revenue up 27.5% and total orders surging 42% to $288M, supercharged by the Paragon and Certrec acquisitions and a booming nuclear power market. However, the quality of these earnings is mixed. Adjusted EBITDA margins compressed by 200 basis points to 21.1%, and operating cash flow nearly halved compared to a year ago. Furthermore, management changed their Adjusted EPS methodology to include stock-based compensation as an expense—a shareholder-friendly move—but simultaneously lowered FY26 EPS guidance due to a one-time CEO retention grant. While the company reaffirmed its full-year EBITDA and Free Cash Flow targets, the Q1 margin hole means they must execute a steep profitability ramp in the remaining three quarters.
🐂 Bull Case
Even excluding the Paragon and Certrec acquisitions, organic orders grew an impressive 19% to $241M. Record capital spending commitments by power plant operators are creating a multi-year tailwind for Mirion's installed base solutions.
Paragon is functioning exactly as planned—serving as the 'tip of the spear' to capture new nuclear upgrades. The integration is on pace and already realizing commercial synergies, pushing total orders up 42%.
🐻 Bear Case
Adjusted EBITDA margins compressed by 200 basis points to 21.1%. While Paragon was previously flagged as near-term dilutive, hitting the reaffirmed FY26 guidance of 25-26% margin now requires flawless execution and significant acceleration in the back half of the year.
Operating cash flow nearly halved YoY to $18.9M due to working capital drains. Additionally, a special CEO retention grant forced a downgrade to FY26 Adjusted EPS guidance, pushing GAAP net income into the red at a $3.4M loss.
⚖️ Verdict: ⚪
Neutral. The order book and nuclear tailwinds are undeniably strong, but the divergence between surging revenue and shrinking cash flow/margins warrants caution until the M&A margin dilution is fully absorbed.
Key Themes
M&A Supercharges Top-Line Growth
Revenue growth is Accelerating dramatically, hitting 27.5% YoY to reach $257.6M. This was heavily fueled by the Paragon and Certrec acquisitions. Total orders jumped 42% to $288M, signaling the acquisitions are executing well and expanding Mirion's addressable footprint in the nuclear sector.
Macro: Power Plant Capex Accelerating
Management explicitly cited 'record capital spending commitments by power plant operators' as the primary engine for demand. This macro tailwind is insulating Mirion from broader industrial weakness, providing a highly visible runway for future revenue.
Cancer Care & Medical Resiliency
Beyond nuclear power, management reaffirmed that the business is capturing momentum in Cancer Care markets. The company continues to roll out new products to 'meet customers where they are headed,' ensuring the non-nuclear segments provide a Stable growth floor.
Margin Compression from M&A
Adjusted EBITDA margin Decelerated from 23.1% in 25Q1 to 21.1% in 26Q1. While management previously noted Paragon would be near-term dilutive, this creates a steep hill to climb. FY26 guidance requires hitting 25-26%, meaning a dramatic acceleration in profitability is required over the next three quarters.
Divergence: Revenue Up, Cash Flow Down
Despite revenue surging 27.5%, Operating Cash Flow is Reversing, decelerating sharply from $35.6M a year ago to $18.9M. A $19.6M cash drain from accrued expenses and other current liabilities severely impacted free cash flow conversion early in the year.
SBC Methodology Change and CEO Grant
The company changed its Adjusted EPS calculation to include stock-based compensation (SBC) as an expense for the current period—a welcome move toward realistic reporting. However, a 'special one-time CEO retention grant' of performance stock options forced a downgrade to FY26 Adj EPS guidance (from $0.50-$0.57 down to $0.48-$0.55), penalizing the bottom line.
Other KPIs
Accelerating. Up 33.2% YoY from $147.9M. This segment is benefiting heavily from the hardware-centric acquisitions and robust equipment demand from the nuclear installed base.
Stable. Up 12.0% YoY from $54.1M. Growing significantly below the company average of 27.5%, but providing a steady, recurring base of high-margin income.
Decelerating from 47.6% in 25Q1. Cost of product revenues grew slightly faster than product revenues, indicating potential mix shifts or integration costs from recent acquisitions weighing on gross profitability.
Guidance
Accelerating vs FY25's growth rate. Reaffirmed. Driven heavily by the full-year inclusion of Paragon and Certrec, alongside foreign exchange tailwinds.
Stable. Reaffirmed. Excludes acquisitions and FX, representing the true underlying demand of the legacy business.
Accelerating trajectory required. Reaffirmed. With Q1 printing a 21.1% margin, achieving the 25.5% midpoint requires significant margin expansion and synergy realization in Q2-Q4.
Decelerating. Revised downward from the prior $0.50 - $0.57 range strictly due to the impact of the April 2026 CEO retention stock option grant, as SBC is now treated as an expense in this metric.
Stable. Reaffirmed. Implies a 54% - 58% conversion of Adjusted EBITDA. Reaching this will require a sharp reversal of the working capital drains experienced in Q1.
Key Questions
Bridge to 25-26% FY Margin
With Q1 Adjusted EBITDA margin coming in at 21.1%, what specific synergies, pricing actions, or product mix shifts give you confidence in hitting the 25.0-26.0% full-year target?
Working Capital Dynamics
Operating cash flow was roughly halved year-over-year despite higher Adjusted EBITDA. What exactly drove the $19.6M headwind in accrued expenses, and do you expect this to reverse in Q2?
CEO Retention Grant Impact
Can you quantify the total expected dollar impact of the special CEO retention grant on stock-based compensation for the remainder of FY26 and FY27?